Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-12-09
2009-08-18
Solola, Taofiq A (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S437000, C514S454000, C546S018000, C549S027000, C549S331000
Reexamination Certificate
active
07576094
ABSTRACT:
The present invention is concerned with certain novel spiro substituted heterocylic ring derivatives. These compounds may be useful in the manufacture of pharmaceutical compositions for treating disorders mediated by lipoxygenases. They may also be useful in the manufacture of pharmaceutical formulations for the treatment of lipoxygenase-mediated disorders.
REFERENCES:
patent: 3331846 (1967-07-01), Easton et al.
patent: 3574627 (1971-04-01), Stern et al.
patent: 4105670 (1978-08-01), Noguchi et al.
patent: 4284644 (1981-08-01), Sugihara et al.
patent: 4330554 (1982-05-01), Sugihara et al.
patent: 4342779 (1982-08-01), Sugihara et al.
patent: 4362740 (1982-12-01), Imada et al.
patent: 4497820 (1985-02-01), Merlini et al.
patent: 4568692 (1986-02-01), Evans
patent: 4571406 (1986-02-01), Evans et al.
patent: 4761403 (1988-08-01), Gunn et al.
patent: 4780469 (1988-10-01), Toda et al.
patent: 4814346 (1989-03-01), Albert et al.
patent: 4831050 (1989-05-01), Cassidy et al.
patent: 4845092 (1989-07-01), Sanger et al.
patent: 4857516 (1989-08-01), Terao et al.
patent: 4918079 (1990-04-01), King
patent: 4950684 (1990-08-01), Koszyk et al.
patent: 5013853 (1991-05-01), Gericke et al.
patent: 5015661 (1991-05-01), Walser
patent: 5021432 (1991-06-01), Yamanaka et al.
patent: 5032591 (1991-07-01), Evans et al.
patent: 5059609 (1991-10-01), Eggler et al.
patent: 5076835 (1991-12-01), Condon et al.
patent: 5112972 (1992-05-01), Gericke et al.
patent: 5126460 (1992-06-01), Faruk
patent: 5143936 (1992-09-01), Yamanaka et al.
patent: 5147866 (1992-09-01), Stemp et al.
patent: 5232938 (1993-08-01), Stemp et al.
patent: 5250547 (1993-10-01), Lochead et al.
patent: 5268386 (1993-12-01), Harada et al.
patent: 5318969 (1994-06-01), Yamanaka et al.
patent: 5350747 (1994-09-01), Howard
patent: 5354729 (1994-10-01), Uekawa et al.
patent: 5387587 (1995-02-01), Häusler et al.
patent: 5393775 (1995-02-01), Le Baut et al.
patent: 5399562 (1995-03-01), Becker et al.
patent: 5591772 (1997-01-01), Lane et al.
patent: 5606006 (1997-02-01), Wang
patent: 5618833 (1997-04-01), Foulon et al.
patent: 5624954 (1997-04-01), Evans et al.
patent: 5643942 (1997-07-01), Hester, Jr. et al.
patent: 5665799 (1997-09-01), Inui et al.
patent: 5674876 (1997-10-01), Gilbert et al.
patent: 5686624 (1997-11-01), Di Malta et al.
patent: 5688810 (1997-11-01), Jones et al.
patent: 5688871 (1997-11-01), Inui et al.
patent: 5696145 (1997-12-01), Foulon et al.
patent: 5698717 (1997-12-01), Iyama et al.
patent: 5728704 (1998-03-01), Mylari et al.
patent: 5798365 (1998-08-01), Kirsch et al.
patent: 5849780 (1998-12-01), Di Malta et al.
patent: 5908860 (1999-06-01), Thompson et al.
patent: 5925673 (1999-07-01), Hellberg et al.
patent: 5939346 (1999-08-01), Marks et al.
patent: 5939452 (1999-08-01), Dombroski et al.
patent: 5948811 (1999-09-01), Chan et al.
patent: 5994350 (1999-11-01), Foulon et al.
patent: 6005007 (1999-12-01), Farmer et al.
patent: 6040308 (2000-03-01), Häusler et al.
patent: 6046341 (2000-04-01), Foulon et al.
patent: 6051601 (2000-04-01), Dombroski et al.
patent: 6090818 (2000-07-01), Foulon et al.
patent: 6117874 (2000-09-01), Dombroski et al.
patent: 6127396 (2000-10-01), Cordi et al.
patent: 6133286 (2000-10-01), Dombroski et al.
patent: 6153627 (2000-11-01), Häusler et al.
patent: 6252090 (2001-06-01), Vasudevan et al.
patent: 6291677 (2001-09-01), Vasudevan et al.
patent: 6313107 (2001-11-01), Vasudevan et al.
patent: 6350759 (2002-02-01), Casara et al.
patent: 6369225 (2002-04-01), Vasudevan et al.
patent: 6596758 (2003-07-01), Brunet et al.
patent: 6652601 (2003-11-01), Sauter et al.
patent: 6956033 (2005-10-01), Ogawa et al.
patent: 2003/0212109 (2003-11-01), Mitchell et al.
patent: 2003/0225057 (2003-12-01), Smith et al.
patent: 2004/0152755 (2004-08-01), He et al.
patent: 2005/0020573 (2005-01-01), Smith et al.
patent: 2005/0020617 (2005-01-01), Bastian et al.
patent: 2005/0065099 (2005-03-01), Walkinshaw et al.
patent: 2005/0065149 (2005-03-01), Wang et al.
patent: 2005/0065150 (2005-03-01), Wang et al.
patent: 2005/0165001 (2005-07-01), Krauss et al.
patent: 2006/0106014 (2006-05-01), Boddupalli et al.
patent: 2006/0193797 (2006-08-01), Zhang et al.
patent: 1004295 (1992-10-01), None
patent: 2053962 (1991-10-01), None
patent: 4020133 (1991-01-01), None
patent: 4018552 (1991-12-01), None
patent: 4115521 (1992-11-01), None
patent: 19854147 (2000-05-01), None
patent: 0003084 (1979-07-01), None
patent: 0488301 (1992-06-01), None
patent: 0636608 (1995-02-01), None
patent: 2242628 (1991-10-01), None
patent: 53-73560 (1978-06-01), None
patent: 1-246274 (1989-10-01), None
patent: 4-264080 (1992-09-01), None
patent: 7-188210 (1995-07-01), None
patent: WO 91/09593 (1991-07-01), None
patent: WO 91/16888 (1991-11-01), None
patent: WO 92/20672 (1992-11-01), None
patent: WO 92/22293 (1992-12-01), None
patent: WO 94/12173 (1994-06-01), None
patent: WO 94/13297 (1994-06-01), None
patent: WO 96/11925 (1996-04-01), None
patent: WO 98/09956 (1998-03-01), None
patent: WO 99/43670 (1999-09-01), None
patent: WO 02/18361 (2002-03-01), None
patent: WO 02/26727 (2002-04-01), None
patent: WO 02/42285 (2002-05-01), None
patent: WO 2005/016335 (2005-02-01), None
patent: WO 2005/016881 (2005-02-01), None
patent: WO 2005/063745 (2005-07-01), None
patent: WO 2005/075463 (2005-08-01), None
patent: WO 2006/093548 (2006-09-01), None
King; Med Chem: Principle and Practice (1994), p. 206-208.
Bernard et al., “The First Synthesis of Some Spiro[2,3-Dihydro-2,2-Dimethylbenzofuran-3,1′-Cyclopropanes] through, Mo(CO)6Catalyzed, One Pot Claisen Rearrangement-Cyclization Reaction of 2-Cyclopropylidene-Aryloxy Alkanes.” Synlett, May 1997, 585-6.
Gilbert et al., “Synthesis, Structure Determination, and Analysis of Spiro[2,3-dihydro-5-hydroxy-4,6,7-trimethylbenzofuran-2,1′- cyclopropane].” Journal of Organic Chemistry, 1992, 5271-6, 57(19).
Kabbe, “A simple synthesis of 4-chromanones.” Synthesis, 1978, 886-7, 12.
Kawada et al., “Spirocyclopropane Compounds. I. Synthesis and Reactivity of Spiro[cyclopropane-1,2′-[2H]indol]-3′(1′H)-ones.” Chemical & Pharmaceutical Bulletin, 1981, 1900-1, 29(7).
Kawada et al., “Spirocyclopropane Compounds. II. Synthesis and Biological Activities of Spiro[cyclopropane-1,2′-[2H]indol]-3′(1′H)-ones.” Chemical & Pharmaceutical Bulletin, 1981, 1912-9, 29(7).
Kawada et al., “Spirocyclopropane Compounds. III. Synthesis of Spiro[benzofuran-2(3H),1′-cyclopropan]-3-ones for Evaluation as Gastric Antisecretory and Antiulcer Agents.” Chemical & Pharmaceutical Bulletin, 1984, 3532-50, 32(9).
Kawada et al., “Spirocyclopropane Compounds. VI. Synthesis of Spiro[benzo[b]-thiophene-2(3H),1′-cyclopropan]-3-ones.” Chemical & Pharmaceutical Bullentin, 1986, 1939-45, 34(5).
Kitazawa et al., “Studies on the Synthesis of Antiulcer Agents.” Yakugaku Zasshi, 1989, 241-9, 109(4)—abstract only.
Manev et al., “ 5-Lipoxygenase as a Putative Link Between Cardiovascular and Psychiatric Disorders.” Critical Reviews in Neurobiology, 2004, 181-6, 16(1-2).
Remers et al., “The Birch Reduction of Typtamine Quaternary Salts.” Tetrahedron Letters, 1968, 81-4, 1.
Rola-Pleszczynski et al., “Cytokine Gene Regulation by PGE2, LTB4 and PAF.” Mediators of Inflammation, 1992, 5-8, vol. 1.
Uz et al., “5-lipoxygenase (5LOX)-deficient Mice Express Reduced Anxiety-like Behavior.” Restorative Neurology and Neuroscience, 2002, 15-20, 20(1-2).
Chen Jian
Chu Daniel T. W.
Cong Qiang
James Donald R.
Li Xianfeng
Eli Lilly and Company
Myers James B.
Solola Taofiq A
LandOfFree
Spiro derivatives as lipoxygenase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Spiro derivatives as lipoxygenase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Spiro derivatives as lipoxygenase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4101657